In this week’s video, Dr. Brian Durie provides insight on how to assess response to various myeloma treatments.

BOTTOM LINE: 

By checking M-protein levels after each cycle of treatment, we can assess the true benefits of each therapy.


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
What is this new Black Swan project called iStopMM?
Next Post
How common are low platelet counts after autologous stem cell transplant?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.